Amarin Corporation plc (AMRN)
NASDAQ: AMRN · Real-Time Price · USD
15.34
-1.03 (-6.29%)
At close: Mar 13, 2026, 4:00 PM EDT
15.04
-0.30 (-1.96%)
After-hours: Mar 13, 2026, 4:59 PM EDT
Amarin Corporation Employees
Amarin Corporation had 275 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
275
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$776,895
Profits / Employee
-$141,084
Market Cap
319.13M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 275 | 0 | - |
| Dec 31, 2023 | 275 | -90 | -24.66% |
| Dec 31, 2022 | 365 | -195 | -34.82% |
| Dec 31, 2021 | 560 | -440 | -44.00% |
| Dec 31, 2020 | 1,000 | 35 | 3.63% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| GSK plc | 66,841 |
| Bristol-Myers Squibb Company | 32,500 |
| Grifols | 23,737 |
| Organon & Co. | 10,000 |
| Biogen | 7,500 |
| Scilex Holding Company | 30 |
AMRN News
- 16 days ago - Amarin Corporation plc (AMRN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease - GlobeNewsWire
- 2 months ago - US Supreme Court to hear 'skinny label' patent fight involving Amarin - Reuters
- 2 months ago - Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization - GlobeNewsWire
- 4 months ago - New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients - GlobeNewsWire
- 4 months ago - Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 - GlobeNewsWire
- 4 months ago - Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress - GlobeNewsWire